Skip to content

Plasma ACTH Precursors measured by Pro-opiomelanocortin (POMC) ELISA as a Predictor of Silent Corticotroph Adenomas.

Aug 2026 · Journal of Clinical Endocrinology and Metabolism · 0 citations
Medicine

TL;DR

Plasma POMC level was found to be a promising predictor of SCA presence in a clinically non-functioning pituitary adenoma (CNFPA) cohort and could become part of the initial CNFPA evaluation and used for monitoring for residual and recurrent tumor after surgery.

Abstract

Background

Silent corticotroph adenomas (SCAs) are only identified after surgical removal and pathological analysis. Defective processing of pro-opiomelanocortin (POMC) may underlie these tumors' failure to secrete biologically active ACTH. While prior studies found elevated plasma POMC in patients with Cushing disease (CD) due to macroadenomas and ectopic ACTH-secreting tumors, plasma POMC has not been measured in a clinically non-functioning pituitary adenoma (CNFPA) cohort. We hypothesized that elevated plasma POMC could serve as a marker of the SCA sub-type of CNFPAs.

Methods

We measured plasma POMC levels in 264 CNFPAs in a prospective, observational study (157 treated surgically and 107 observed without surgery), 10 known SCAs, and 3 patients with CD using a POMC 2-site ELISA that detects POMC and pro-ACTH but not ACTH. Surgically removed tumors underwent immunohistochemistry to classify them into SCA and Not SCA subtypes. Normal POMC levels were < 39 fmol/mL.

Results

POMC levels were higher in SCA (n = 7) than Not SCA (n = 138) groups (median 73 vs. 14 fmol/mL, p < 0.001) and elevated (≥ 39 fmol/mL) in 85.7% of SCAs. Elevated POMC predicted SCA presence amongst CNFPAs with a sensitivity of 85.7% and specificity of 97.9%. POMC was elevated in all known SCAs with visible residual tumor, ranging from 49.6 to 3796 fmol/mL.

Conclusion

We found plasma POMC level to be a promising predictor of SCA presence in a CNFPA cohort. POMC measurement could become part of the initial CNFPA evaluation and used for monitoring for residual and recurrent tumor after surgery. These preliminary findings warrant further investigation.

View source

Similar papers

Open access Aug 2026

The ACTH × DHEAS product as an ancillary biomarker of mild autonomous cortisol secretion in adrenal incidentalomas

Introduction: Mild autonomous cortisol secretion (MACS) is usually classified by the 1-mg overnight dexamethasone suppression test (DST). However, a single post-DST cortisol value may not fully capture the chronicity or biological relevance of cortisol autonomy. Although adrenocorticotropic hormone (ACTH) and dehydroep...

Ümit Çavdar, Ö. Eren, Tuğçe Tekinaslan et al. · 0 citations
Open access Sep 2026

Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests.

In Japan, the Corticotropin-releasing hormone (CRH) stimulation test is widely used to evaluate secondary adrenal insufficiency (SAI); however, the insulin tolerance test (ITT) is sometimes required to assess hypothalamic dysfunction. This study aimed to identify the clinical conditions in which the ITT is necessary in...

Nanami Okada, Tomoko Nakagawa, Noboru Murahashi et al. · 0 citations
Review Open access Aug 2026

Mild autonomous ACTH secretion: a narrative review of 52 cases from the literature.

Mild autonomous ACTH secretion (MAAS) is an autonomous pituitary-derived hypercortisolism occurring in the absence of overt signs and symptoms of Cushing's syndrome (CS). MAAS is still an underdiagnosed and poorly understood condition. We systematically collected 52 cases of MAAS published in the literature from 1994 t...

Federico Nicoli, C. Eller-Vainicher, Renato Cesare Cozzi et al. · 0 citations
Sep 2026

Clinical Utilization of CYP17A1 and CYP11B2 in Evaluating Cortisol- and Aldosterone-Producing Adrenal Nodules.

Mild autonomous cortisol secretion (MACS) has been increasingly recognized as a risk factor for cardiometabolic comorbidities and increased mortality. While CYP11B2 immunohistochemistry (IHC) based HISTALDO classification is well established for evaluating primary aldosteronism (PA), the clinical utility of CYP17A1 IHC...

P. J. Sarmadian, E. Baraban, Tamara L. Lotan et al. · 0 citations
Open access Sep 2026

Case Report: Somatic GNAS and CACNA1D mutations responsible for adrenal cortisol-producing adenoma with multiple aldosterone-producing micronodules—concurrence of primary aldosteronism and mild autonomous cortisol secretion

The concurrent presence of primary aldosteronism (PA) and mild autonomous cortisol secretion (MACS) caused by adrenal lesions of a solitary cortisol-producing adenoma, accompanied by multiple aldosterone-producing micronodules (MAPM), is exceptionally rare. Moreover, there is a notable paucity of data regarding the...

Ling-Na Deng, Yin-Chun Jin, Yi-Han Dong et al. · 0 citations
Aug 2026

Calcified pituitary adenomas: First comprehensive characterization of a distinct clinical entity driven by GNAQ-mediated calcium-mitochondrial axis.

Calcification in pituitary adenomas is a rare phenomenon, observed in only 0.2% to 8% of imaging studies and 5.4% to 25% of histopathological analyses, which complicates diagnosis and surgical intervention, yet its molecular underpinnings remain largely unknown. In this study, we retrospectively analyzed 115 patients w...

Changjun Rao, L. Gong, Jingyuan Jia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.